Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license

Standard

PR segment duration

MEIS1 · rs11678354

Strength of the evidence

1 / 4

Its strongest genetic-study result is p = 10−8, with 1 associations in the GWAS Catalog.

How this is scored

4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.

What the study found

Who was studied 16,468 European ancestry individuals.

The effect Each copy of the A allele shifted the measure 1.26 higher (95% confidence interval 0.84-1.68); p = 5 × 10−9.

How common The A allele had a frequency of about 36% in the people studied.

Where it sits Chromosome 2, band 2p14 — in an intron of MEIS1.

How common each version is

AT
Korean Korea4K
A 5.6% · T 94.4%
Korean Korea1K
A 5.5% · T 94.5%
Japanese ToMMo
A 11.8% · T 88.2%
Vietnamese
A 3.7% · T 96.3%
World gnomAD
A 23.5% · T 76.5%
World 1000 Genomes
A 14.8% · T 85.2%
World TOPMed
A 21.6% · T 78.4%

By ancestry gnomAD

East Asian
A 6.4% · T 93.7%
European (non-Finnish)
A 32.7% · T 67.3%
African / African American
A 9.8% · T 90.2%
South Asian
A 14.0% · T 86.0%
Admixed American (Latino)
A 19.9% · T 80.1%
Middle Eastern
A 31.6% · T 68.4%
Finnish
A 34.8% · T 65.2%
Ashkenazi Jewish
A 26.4% · T 73.6%

The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.

What each result means

A/A Two copies of the version the research linked to PR segment duration. That is the strongest link of the three results. A link in a study is not a diagnosis.
A/T One copy of the version the research linked to PR segment duration. That is a smaller link than two copies.
T/T No copy of the version the research linked to PR segment duration. This is the starting point the study compared everyone against.
Source

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

PR segment duration (rs11678354). MyGeneLog™. https://www.mygenelog.com/variants/rs11678354

← See all variants